TITLE

MEDICINOVA REPORTS POSITIVE RESULTS FOR PHASE I OF MN-029

PUB. DATE
November 2007
SOURCE
Worldwide Biotech;Nov2007, Vol. 19 Issue 11, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that MediciNova Inc., a biopharmaceutical company based in San Diego, California and is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, has announced that it presented positive findings from a Phase I clinical study of MN-029, its novel vascular disrupting agent (VDA), at the 14th European Cancer Conference (ECCO 14) in Barcelona, Spain. The clinical trial enrolled 34 patients at two centers in the U.S., according to the company.
ACCESSION #
27199635

 

Related Articles

  • Nontoxicity Endpoints in Phase I Trial Design for Targeted, Non-Cytotoxic Agents. Korn, Edward L. // JNCI: Journal of the National Cancer Institute;7/7/2004, Vol. 96 Issue 13, p977 

    Examines why so few phase I trials for cytotoxic agents are using nontoxicity endpoints. Challenges in using these nontraditonal endpoints; Difficulty of defining the desired target effect; Practical difficulties in measuring these effects once they have been defined because of the lack of...

  • Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. Rudick, Richard A.; Stuart, William H.; Calabresi, Peter A.; Confavreux, Christian; Galetta, Steven L.; Radue, Ernst-Wilhelm; Lublin, Fred D.; Weinstock-Guttman, Bianca; Wynn, Daniel R.; Lynn, Frances; Panzara, Michael A.; Sandrock, Alfred W. // New England Journal of Medicine;3/2/2006, Vol. 354 Issue 9, p911 

    Background: Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an α4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies....

  • Date set for ACT India course.  // European Pharmaceutical Executive;Jun2007, p11 

    The article provides information on the 2007 Special Edition Short Course of "Applied Clinical Trials" entitled Conducting Clinical Trials in India, which will be held on June 26, 2007 at the Copthorne Tara Hotel in England. It is an intensive one-day seminar that is designed to provide an...

  • They're Dying to Get In. Bjerklie, David // Time International (South Pacific Edition);4/22/2002, Issue 15, p55 

    Discusses the difficulty of being able to participate in clinical trials in medicine. Benefits of the trials, including substantial doctor-patient interaction; Idea that it is not just the terminally ill who benefit from the attention, but also medically neglected or poorly informed subjects...

  • A Revised Approach to Early Trials. Priestley, Anthony // Applied Clinical Trials;Sep2008, Vol. 17 Issue 9, p90 

    The author reflects on the need to adopt new ways of designing and conducting early trials in the U.S. He suggests that data generated only in health volunteers can lead to erroneous conclusions about the likely behavior of a drug. He adds that ethical arguments may direct a company toward Phase...

  • How to Find a Trial. Smith, Ian K. // Time;11/22/1999, Vol. 154 Issue 21, p114 

    Offers information on patient enrollment in clinical drug trials. Researchers' need for patients as well as patients' need for treatment; Reasons adults do not participate in clinical drug trials; Where to locate trials. INSETS: Ace-ing It, by Janice M. Horowitz;Inside Information, by Janice...

  • ECCO Meeting.  // BioWorld Today;9/28/2007, Vol. 18 Issue 189, p4 

    The article reports on the positive findings from the Phase I study of MN-029, conducted by MediciNova Inc. in 2007. The MN-029 is a vascular disrupting agent which shutdown tumor blood flow that causes central necrosis of solid tumors. According to the article, the study which is categorized as...

  • The Changing Landscape.  // Applied Clinical Trials;Feb2004, Vol. 13 Issue 2, p12 

    Presents an overview of the articles published in the February 2004 issue of the periodical "Applied Clinical Trials." Highlights of the ACT 2004 summit which will be held in Munich, Germany on May 2004; Discussion of the suitability, efficiency and effectiveness of the Italian clinical trial...

  • Phase IIIb Extensive Clinical Studies.  // Applied Clinical Trials;Feb2004, Vol. 13 Issue 2, p44 

    Discusses the activation process of two large Phase IIIb studies, concurrently implemented in a global network of hundreds of Italian centers under the coordination of a single team involving the sponsor. Examination of the overall performance of the Italian clinical trial system regarding the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics